Form 4 for IOVA IOVANCE BIOTHERAPEUTICS, INC.
Accepted 2024-02-20 00:00:00 ET · period of report 2024-02-20 · accession 0001104659-24-025520 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-02-20 | 2024-02-20 | IOVA | Rothbaum Wayne P. | Dir | P - Purchase | $9.15 | +5.00M | 28.07M | +22% | +$45.75M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-20 | P | A | 5,000,000 | $9.15 | 28,067,333 | I By Quogue Capital LLC | — | — | (F3) Such shares purchased pursuant to Issuer's underwritten offering, which priced on 02/20/2024. (F2) The numbers reported in column 5 exclude 1,932,667 shares of common stock underlying 1,932,667 shares of Series B Preferred Stock of the Issuer beneficially owned by Quogue Capital LLC. (F1) Such shares may be held directly by Quogue Capital LLC or are held by one or more entities controlled by Quogue Capital LLC. The reporting person is the sole managing member of Quogue Capital LLC, and therefore, he is deemed to beneficially own such shares of common stock of the Issuer. |